AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Are We Rewarding and Returning Capital to Risk Takers?
"I sensed that I was talking to a politician. So it's not thinking of there was malevolence there or benevolence," he says. "Every single question in that interview was a challenging one but it wasn't grilling, which is what people seem to want to do with pharmaceutical companies." He asks: How do we reward and return capital to risk takers who will spend a billion dollars on a disease that maybe only harms a single digit percentage of the population?